Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm neoadjuvant osimertinib study in resectable EGFR-mutant NSCLC
MOH_2024-01-22_013135Phase 2Not yet recruiting
- Sponsor
- פרו' יאיר בר
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by פרו' יאיר בר. Primary endpoint: Identification of EGFR inhibitor resistance mechanisms. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2024-01-22_013135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-22_013135.